Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 344 participants.

Also called NCT07179380

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 344 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07179380
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Colombia, Czechia, Denmark, France, Georgia, Germany, Greece, Israel, Italy, Japan, Malaysia, Mexico, New Zealand, Philippines, Poland, Portugal, Romania, Serbia, South Korea, Spain, Switzerland, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07179380. Randomized; double masking; primary purpose treatment. Start 2026-01-07 (actual); primary completion 2028-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Acronym
PALM-ILD
Condition
Interstitial Lung Disease
Intervention (Drug)
Treprostinil Palmitil Inhalation Powder
Intervention (Drug)
Placebo
Lead sponsor
Insmed Incorporated (class: industry)

Record details

Record id
cardio:ct-nct07179380
Content hash
ff460c2a5c543bc35381a270c24efd3424ce9e01bdc858fe80cec423b023389d